Lakefront Biotherapeutics (LKFT) Other Operating Expenses (2016 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Other Operating Expenses for 11 consecutive years, with $1.2 million the latest figure, recorded in Q1 2026.

• Quarterly Other Operating Expenses fell 83.59% year-over-year to $1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.3 billion (down 1589.01% YoY) and the FY2025 annual result came in at $60.9 million, up 31.2% from the prior year.
• Other Operating Expenses grew to $1.2 million in Q1 2026 per LKFT's latest filing, from -$1.3 billion in the prior quarter.
• Over the last five years, Other Operating Expenses for LKFT reached as high as $64.0 million in Q4 2024 and fell as low as -$1.3 billion in Q4 2025.
• A 5-year average of -$70.8 million and a median of $9.7 million in 2022 frame the typical range for Other Operating Expenses.
• Annual changes were most pronounced in 2024 — Other Operating Expenses surged 332.31% — and 2025, when it sank 2183.24%.
• Year by year, Other Operating Expenses stood at $7.6 million in 2022, then surged by 95.4% to $14.8 million in 2023, then jumped by 332.31% to $64.0 million in 2024, then plunged by 2183.24% to -$1.3 billion in 2025, then surged by 100.09% to $1.2 million in 2026.
• According to Business Quant data, Other Operating Expenses over the past three periods registered $1.2 million, -$1.3 billion, and $5.7 million for Q1 2026, Q4 2025, and Q2 2025 respectively.